Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

INTRODUCTION: This post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Yale, Jean-François, Bodholdt, Ulrik, Catarig, Andrei-Mircea, Catrina, Sergiu, Clark, Alice, Ekberg, Neda Rajamand, Erhan, Umut, Holmes, Patrick, Knudsen, Søren Tang, Liutkus, Joanne, Sathyapalan, Thozhukat, Schultes, Bernd, Rudofsky, Gottfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical care/Education/Nutrition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984040/
https://www.ncbi.nlm.nih.gov/pubmed/35383100
http://dx.doi.org/10.1136/bmjdrc-2021-002619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984040/
https://www.ncbi.nlm.nih.gov/pubmed/35383100
http://dx.doi.org/10.1136/bmjdrc-2021-002619

Ejemplares similares